Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Sees Significant Decline in Short Interest

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Get Free Report) was the recipient of a significant drop in short interest in August. As of August 14th, there was short interest totaling 56,253 shares, a drop of 55.4% from the July 30th total of 126,080 shares. Based on an average daily volume of 140,397 shares, the short-interest ratio is currently 0.4 days. Approximately 2.5% of the company’s stock are short sold.

Lakewood-Amedex Biotherapeutics Price Performance

NASDAQ:LABT traded up $0.01 during trading hours on Monday, hitting $2.31. The company’s stock had a trading volume of 65,163 shares, compared to its average volume of 1,163,603. Lakewood-Amedex Biotherapeutics has a 52-week low of $1.66 and a 52-week high of $98.20. The company has a market capitalization of $5.47 million and a PE ratio of -0.49. The company has a fifty day simple moving average of $2.54.

Get Lakewood-Amedex Biotherapeutics alerts:

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($2.75) earnings per share (EPS) for the quarter. As a group, analysts predict that Lakewood-Amedex Biotherapeutics will post 2.52 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on LABT shares. Wall Street Zen cut Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Weiss Ratings assumed coverage on Lakewood-Amedex Biotherapeutics in a research report on Monday, July 20th. They set a “sell (e-)” rating for the company. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Check Out Our Latest Analysis on Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics Company Profile

(Get Free Report)

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.

Read More

• Five stocks we like better than Lakewood-Amedex Biotherapeutics
• Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
• Insiders Are Betting Big on These 3 Healthcare Stocks
• 3 Stocks for Investors Who Still Believe Cash Is King
• Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason

Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.